As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

On the other hand, if the FDA rejects Annexon's filing, Annexon may have to go back and revise its RWE study or even open a ...

Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.